CD44 and neoplasm: Carfilzomib-loaded nanoparticles were encapsulated in neutrophil-derived vesicles. Neutrophil vesicles targeted circulating tumor cells and premetastatic lesion through three pairs of interactions including LFA-1/ICAM-1, β1 integrin/VCAM-1, and CD44/L-selectin.